AustralieFrV1, PascalFrancis, Corpus, bibRecord, 006229

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2

Identifieur interne : 006229 ( PascalFrancis/Corpus ); précédent : 006228; suivant : 006230

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2

Auteurs : P. Brooks ; P. Emery ; J. F. Evans ; H. Fenner ; C. J. Hawkey ; C. Patrono ; J. Smolen ; F. Breedveld ; R. Day ; M. Dougados ; E. W. Ehrich ; J. Gijon-Banos ; T. K. Kvien ; M. H. Van Rijswijk ; T. Warner ; H. Zeidler

Source :

Rheumatology:(Oxford) [ 1462-0324 ] ; 1999.

RBID : Pascal:99-0464747

Descripteurs français

Pascal (Inist)
- Antiinflammatoire non stéroïde, Prostaglandin-endoperoxide synthase, Isozyme, Forme moléculaire, Pharmacologie, Mécanisme action, Spécificité, In vitro, In vivo, Homme, Traitement, Chimiothérapie.

English descriptors

KwdEn :
- Chemotherapy, Human, In vitro, In vivo, Isozyme, Mechanism of action, Molecular form, Non steroidal antiinflammatory agent, Pharmacology, Prostaglandin-endoperoxide synthase, Specificity, Treatment.

Abstract

The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`2`		`@0 1462-0324`
A05				`@2 38`
A06				`@2 8`
A08	`01`	`1`	`ENG`	`@1 Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2`
A11	`01`	`1`		`@1 BROOKS (P.)`
A11	`02`	`1`		`@1 EMERY (P.)`
A11	`03`	`1`		`@1 EVANS (J. F.)`
A11	`04`	`1`		`@1 FENNER (H.)`
A11	`05`	`1`		`@1 HAWKEY (C. J.)`
A11	`06`	`1`		`@1 PATRONO (C.)`
A11	`07`	`1`		`@1 SMOLEN (J.)`
A11	`08`	`1`		`@1 BREEDVELD (F.)`
A11	`09`	`1`		`@1 DAY (R.)`
A11	`10`	`1`		`@1 DOUGADOS (M.)`
A11	`11`	`1`		`@1 EHRICH (E. W.)`
A11	`12`	`1`		`@1 GIJON-BANOS (J.)`
A11	`13`	`1`		`@1 KVIEN (T. K.)`
A11	`14`	`1`		`@1 VAN RIJSWIJK (M. H.)`
A11	`15`	`1`		`@1 WARNER (T.)`
A11	`16`	`1`		`@1 ZEIDLER (H.)`
A14	`01`			`@1 Faculty of Health Sciences, University of Queensland @3 AUS @Z 1 aut.`
A14	`02`			`@1 Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds @3 GBR @Z 2 aut.`
A14	`03`			`@1 Human Genetics Department, Merck & Co. Inc. @2 West Point, PA @3 USA @Z 3 aut.`
A14	`04`			`@1 Swiss Federal Institute of Technology @2 Zurich @3 CHE @Z 4 aut.`
A14	`05`			`@1 Division of Gastroenterology, University Hospital @2 Nottingham @3 GBR @Z 5 aut.`
A14	`06`			`@1 Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1 @2 Chieti @3 ITA @Z 6 aut.`
A14	`07`			`@1 2nd Department of Medicine, Lainz Hospital @2 Vienna @3 AUT @Z 7 aut.`
A14	`08`			`@1 Leiden University Hospital, Department of Rheumatology @2 Leiden @3 NLD @Z 8 aut.`
A14	`09`			`@1 St Vincent's Hospital @2 Darlinghurst, NSW @3 AUS @Z 9 aut.`
A14	`10`			`@1 Institut de Rheumatologie, Hospital Cochin @2 Paris @3 FRA @Z 10 aut.`
A14	`11`			`@1 Merck & Co. Inc. @2 Rahway, NJ @3 USA @Z 11 aut.`
A14	`12`			`@1 University Hospital @2 Madrid @3 ESP @Z 12 aut.`
A14	`13`			`@1 Oslo City Department of Rheumatology, Diakonhjemmet Hospital @3 NOR @Z 13 aut.`
A14	`14`			`@1 Department of Rheumatology, University Hospital @2 Groningen @3 NLD @Z 14 aut.`
A14	`15`			`@1 Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry @2 London @3 GBR @Z 15 aut.`
A14	`16`			`@1 Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover @3 DEU @Z 16 aut.`
A20				`@1 779-788`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 14528 @5 354000089142290220`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 93 ref.`
A47	`01`	`1`		`@0 99-0464747`
A60				`@1 P @3 C`
A61				`@0 A`
A64	`01`	`2`		`@0 Rheumatology:(Oxford)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.
C02	`01`	`X`		`@0 002B02L`
C03	`01`	`X`	`FRE`	`@0 Antiinflammatoire non stéroïde @5 01`
C03	`01`	`X`	`ENG`	`@0 Non steroidal antiinflammatory agent @5 01`
C03	`01`	`X`	`SPA`	`@0 Antiinflamatorio no esteroide @5 01`
C03	`02`	`X`	`FRE`	`@0 Prostaglandin-endoperoxide synthase @2 FE @5 02`
C03	`02`	`X`	`ENG`	`@0 Prostaglandin-endoperoxide synthase @2 FE @5 02`
C03	`02`	`X`	`SPA`	`@0 Prostaglandin-endoperoxide synthase @2 FE @5 02`
C03	`03`	`X`	`FRE`	`@0 Isozyme @5 03`
C03	`03`	`X`	`ENG`	`@0 Isozyme @5 03`
C03	`03`	`X`	`SPA`	`@0 Isozima @5 03`
C03	`04`	`X`	`FRE`	`@0 Forme moléculaire @5 04`
C03	`04`	`X`	`ENG`	`@0 Molecular form @5 04`
C03	`04`	`X`	`SPA`	`@0 Forma molecular @5 04`
C03	`05`	`X`	`FRE`	`@0 Pharmacologie @5 05`
C03	`05`	`X`	`ENG`	`@0 Pharmacology @5 05`
C03	`05`	`X`	`SPA`	`@0 Farmacología @5 05`
C03	`06`	`X`	`FRE`	`@0 Mécanisme action @5 06`
C03	`06`	`X`	`ENG`	`@0 Mechanism of action @5 06`
C03	`06`	`X`	`SPA`	`@0 Mecanismo acción @5 06`
C03	`07`	`X`	`FRE`	`@0 Spécificité @5 07`
C03	`07`	`X`	`ENG`	`@0 Specificity @5 07`
C03	`07`	`X`	`SPA`	`@0 Especificidad @5 07`
C03	`08`	`X`	`FRE`	`@0 In vitro @5 08`
C03	`08`	`X`	`ENG`	`@0 In vitro @5 08`
C03	`08`	`X`	`SPA`	`@0 In vitro @5 08`
C03	`09`	`X`	`FRE`	`@0 In vivo @5 09`
C03	`09`	`X`	`ENG`	`@0 In vivo @5 09`
C03	`09`	`X`	`SPA`	`@0 In vivo @5 09`
C03	`10`	`X`	`FRE`	`@0 Homme @5 10`
C03	`10`	`X`	`ENG`	`@0 Human @5 10`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 10`
C03	`11`	`X`	`FRE`	`@0 Traitement @5 11`
C03	`11`	`X`	`ENG`	`@0 Treatment @5 11`
C03	`11`	`X`	`SPA`	`@0 Tratamiento @5 11`
C03	`12`	`X`	`FRE`	`@0 Chimiothérapie @5 12`
C03	`12`	`X`	`ENG`	`@0 Chemotherapy @5 12`
C03	`12`	`X`	`SPA`	`@0 Quimioterapia @5 12`
C07	`01`	`X`	`FRE`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`ENG`	`@0 Oxidoreductases @2 FE`
C07	`01`	`X`	`SPA`	`@0 Oxidoreductases @2 FE`
C07	`02`	`X`	`FRE`	`@0 Enzyme`
C07	`02`	`X`	`ENG`	`@0 Enzyme`
C07	`02`	`X`	`SPA`	`@0 Enzima`
N21				`@1 298`

Format Inist (serveur)

NO :	PASCAL 99-0464747 INIST
ET :	Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
AU :	BROOKS (P.); EMERY (P.); EVANS (J. F.); FENNER (H.); HAWKEY (C. J.); PATRONO (C.); SMOLEN (J.); BREEDVELD (F.); DAY (R.); DOUGADOS (M.); EHRICH (E. W.); GIJON-BANOS (J.); KVIEN (T. K.); VAN RIJSWIJK (M. H.); WARNER (T.); ZEIDLER (H.)
AF :	Faculty of Health Sciences, University of Queensland/Australie (1 aut.); Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds/Royaume-Uni (2 aut.); Human Genetics Department, Merck & Co. Inc./West Point, PA/Etats-Unis (3 aut.); Swiss Federal Institute of Technology/Zurich/Suisse (4 aut.); Division of Gastroenterology, University Hospital/Nottingham/Royaume-Uni (5 aut.); Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1/Chieti/Italie (6 aut.); 2nd Department of Medicine, Lainz Hospital/Vienna/Autriche (7 aut.); Leiden University Hospital, Department of Rheumatology/Leiden/Pays-Bas (8 aut.); St Vincent's Hospital/Darlinghurst, NSW/Australie (9 aut.); Institut de Rheumatologie, Hospital Cochin/Paris/France (10 aut.); Merck & Co. Inc./Rahway, NJ/Etats-Unis (11 aut.); University Hospital/Madrid/Espagne (12 aut.); Oslo City Department of Rheumatology, Diakonhjemmet Hospital/Norvège (13 aut.); Department of Rheumatology, University Hospital/Groningen/Pays-Bas (14 aut.); Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry/London/Royaume-Uni (15 aut.); Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover/Allemagne (16 aut.)
DT :	Publication en série; Compte-rendu; Niveau analytique
SO :	Rheumatology:(Oxford); ISSN 1462-0324; Royaume-Uni; Da. 1999; Vol. 38; No. 8; Pp. 779-788; Bibl. 93 ref.
LA :	Anglais
EA :	The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.
CC :	002B02L
FD :	Antiinflammatoire non stéroïde; Prostaglandin-endoperoxide synthase; Isozyme; Forme moléculaire; Pharmacologie; Mécanisme action; Spécificité; In vitro; In vivo; Homme; Traitement; Chimiothérapie
FG :	Oxidoreductases; Enzyme
ED :	Non steroidal antiinflammatory agent; Prostaglandin-endoperoxide synthase; Isozyme; Molecular form; Pharmacology; Mechanism of action; Specificity; In vitro; In vivo; Human; Treatment; Chemotherapy
EG :	Oxidoreductases; Enzyme
SD :	Antiinflamatorio no esteroide; Prostaglandin-endoperoxide synthase; Isozima; Forma molecular; Farmacología; Mecanismo acción; Especificidad; In vitro; In vivo; Hombre; Tratamiento; Quimioterapia
LO :	INIST-14528.354000089142290220
ID :	99-0464747

Links to Exploration step

Pascal:99-0464747

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</title>
<author><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Health Sciences, University of Queensland</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name>
<affiliation><inist:fA14 i1="02"><s1>Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name>
<affiliation><inist:fA14 i1="03"><s1>Human Genetics Department, Merck & Co. Inc.</s1>
<s2>West Point, PA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name>
<affiliation><inist:fA14 i1="04"><s1>Swiss Federal Institute of Technology</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name>
<affiliation><inist:fA14 i1="05"><s1>Division of Gastroenterology, University Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name>
<affiliation><inist:fA14 i1="06"><s1>Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name>
<affiliation><inist:fA14 i1="07"><s1>2nd Department of Medicine, Lainz Hospital</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name>
<affiliation><inist:fA14 i1="08"><s1>Leiden University Hospital, Department of Rheumatology</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name>
<affiliation><inist:fA14 i1="09"><s1>St Vincent's Hospital</s1>
<s2>Darlinghurst, NSW</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name>
<affiliation><inist:fA14 i1="10"><s1>Institut de Rheumatologie, Hospital Cochin</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name>
<affiliation><inist:fA14 i1="11"><s1>Merck & Co. Inc.</s1>
<s2>Rahway, NJ</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gijon Banos, J" sort="Gijon Banos, J" uniqKey="Gijon Banos J" first="J." last="Gijon-Banos">J. Gijon-Banos</name>
<affiliation><inist:fA14 i1="12"><s1>University Hospital</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name>
<affiliation><inist:fA14 i1="13"><s1>Oslo City Department of Rheumatology, Diakonhjemmet Hospital</s1>
<s3>NOR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Rheumatology, University Hospital</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name>
<affiliation><inist:fA14 i1="15"><s1>Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name>
<affiliation><inist:fA14 i1="16"><s1>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</s1>
<s3>DEU</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0464747</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0464747 INIST</idno>
<idno type="RBID">Pascal:99-0464747</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">006229</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</title>
<author><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Health Sciences, University of Queensland</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name>
<affiliation><inist:fA14 i1="02"><s1>Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name>
<affiliation><inist:fA14 i1="03"><s1>Human Genetics Department, Merck & Co. Inc.</s1>
<s2>West Point, PA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name>
<affiliation><inist:fA14 i1="04"><s1>Swiss Federal Institute of Technology</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name>
<affiliation><inist:fA14 i1="05"><s1>Division of Gastroenterology, University Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name>
<affiliation><inist:fA14 i1="06"><s1>Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name>
<affiliation><inist:fA14 i1="07"><s1>2nd Department of Medicine, Lainz Hospital</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name>
<affiliation><inist:fA14 i1="08"><s1>Leiden University Hospital, Department of Rheumatology</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name>
<affiliation><inist:fA14 i1="09"><s1>St Vincent's Hospital</s1>
<s2>Darlinghurst, NSW</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name>
<affiliation><inist:fA14 i1="10"><s1>Institut de Rheumatologie, Hospital Cochin</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name>
<affiliation><inist:fA14 i1="11"><s1>Merck & Co. Inc.</s1>
<s2>Rahway, NJ</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gijon Banos, J" sort="Gijon Banos, J" uniqKey="Gijon Banos J" first="J." last="Gijon-Banos">J. Gijon-Banos</name>
<affiliation><inist:fA14 i1="12"><s1>University Hospital</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name>
<affiliation><inist:fA14 i1="13"><s1>Oslo City Department of Rheumatology, Diakonhjemmet Hospital</s1>
<s3>NOR</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name>
<affiliation><inist:fA14 i1="14"><s1>Department of Rheumatology, University Hospital</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>14 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name>
<affiliation><inist:fA14 i1="15"><s1>Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>15 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name>
<affiliation><inist:fA14 i1="16"><s1>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</s1>
<s3>DEU</s3>
<sZ>16 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Rheumatology:(Oxford)</title>
<idno type="ISSN">1462-0324</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Rheumatology:(Oxford)</title>
<idno type="ISSN">1462-0324</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chemotherapy</term>
<term>Human</term>
<term>In vitro</term>
<term>In vivo</term>
<term>Isozyme</term>
<term>Mechanism of action</term>
<term>Molecular form</term>
<term>Non steroidal antiinflammatory agent</term>
<term>Pharmacology</term>
<term>Prostaglandin-endoperoxide synthase</term>
<term>Specificity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antiinflammatoire non stéroïde</term>
<term>Prostaglandin-endoperoxide synthase</term>
<term>Isozyme</term>
<term>Forme moléculaire</term>
<term>Pharmacologie</term>
<term>Mécanisme action</term>
<term>Spécificité</term>
<term>In vitro</term>
<term>In vivo</term>
<term>Homme</term>
<term>Traitement</term>
<term>Chimiothérapie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="2"><s0>1462-0324</s0>
</fA01>
<fA05><s2>38</s2>
</fA05>
<fA06><s2>8</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BROOKS (P.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>EMERY (P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>EVANS (J. F.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>FENNER (H.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HAWKEY (C. J.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>PATRONO (C.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SMOLEN (J.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BREEDVELD (F.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>DAY (R.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>DOUGADOS (M.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>EHRICH (E. W.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>GIJON-BANOS (J.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>KVIEN (T. K.)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>VAN RIJSWIJK (M. H.)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>WARNER (T.)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>ZEIDLER (H.)</s1>
</fA11>
<fA14 i1="01"><s1>Faculty of Health Sciences, University of Queensland</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Human Genetics Department, Merck & Co. Inc.</s1>
<s2>West Point, PA</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Swiss Federal Institute of Technology</s1>
<s2>Zurich</s2>
<s3>CHE</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Division of Gastroenterology, University Hospital</s1>
<s2>Nottingham</s2>
<s3>GBR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1</s1>
<s2>Chieti</s2>
<s3>ITA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>2nd Department of Medicine, Lainz Hospital</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Leiden University Hospital, Department of Rheumatology</s1>
<s2>Leiden</s2>
<s3>NLD</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>St Vincent's Hospital</s1>
<s2>Darlinghurst, NSW</s2>
<s3>AUS</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Institut de Rheumatologie, Hospital Cochin</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Merck & Co. Inc.</s1>
<s2>Rahway, NJ</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>University Hospital</s1>
<s2>Madrid</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="13"><s1>Oslo City Department of Rheumatology, Diakonhjemmet Hospital</s1>
<s3>NOR</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="14"><s1>Department of Rheumatology, University Hospital</s1>
<s2>Groningen</s2>
<s3>NLD</s3>
<sZ>14 aut.</sZ>
</fA14>
<fA14 i1="15"><s1>Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>15 aut.</sZ>
</fA14>
<fA14 i1="16"><s1>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</s1>
<s3>DEU</s3>
<sZ>16 aut.</sZ>
</fA14>
<fA20><s1>779-788</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>14528</s2>
<s5>354000089142290220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>93 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0464747</s0>
</fA47>
<fA60><s1>P</s1>
<s3>C</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="2"><s0>Rheumatology:(Oxford)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02L</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Antiinflammatoire non stéroïde</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Non steroidal antiinflammatory agent</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Antiinflamatorio no esteroide</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Prostaglandin-endoperoxide synthase</s0>
<s2>FE</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Prostaglandin-endoperoxide synthase</s0>
<s2>FE</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Prostaglandin-endoperoxide synthase</s0>
<s2>FE</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Isozyme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Isozyme</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Isozima</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Forme moléculaire</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Molecular form</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Forma molecular</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pharmacologie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Pharmacology</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Farmacología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Mécanisme action</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Mechanism of action</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Mecanismo acción</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Spécificité</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Specificity</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Especificidad</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>In vitro</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>In vitro</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>In vitro</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>In vivo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>In vivo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>In vivo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0>
</fC07>
<fN21><s1>298</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0464747 INIST</NO>
<ET>Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</ET>
<AU>BROOKS (P.); EMERY (P.); EVANS (J. F.); FENNER (H.); HAWKEY (C. J.); PATRONO (C.); SMOLEN (J.); BREEDVELD (F.); DAY (R.); DOUGADOS (M.); EHRICH (E. W.); GIJON-BANOS (J.); KVIEN (T. K.); VAN RIJSWIJK (M. H.); WARNER (T.); ZEIDLER (H.)</AU>
<AF>Faculty of Health Sciences, University of Queensland/Australie (1 aut.); Rheumatology and Rehabilitation Research Unit, Research School of Medicine, University of Leeds/Royaume-Uni (2 aut.); Human Genetics Department, Merck & Co. Inc./West Point, PA/Etats-Unis (3 aut.); Swiss Federal Institute of Technology/Zurich/Suisse (4 aut.); Division of Gastroenterology, University Hospital/Nottingham/Royaume-Uni (5 aut.); Università di Chieti ' G.D'Annunzio', Cattedra di Farmacologia 1/Chieti/Italie (6 aut.); 2nd Department of Medicine, Lainz Hospital/Vienna/Autriche (7 aut.); Leiden University Hospital, Department of Rheumatology/Leiden/Pays-Bas (8 aut.); St Vincent's Hospital/Darlinghurst, NSW/Australie (9 aut.); Institut de Rheumatologie, Hospital Cochin/Paris/France (10 aut.); Merck & Co. Inc./Rahway, NJ/Etats-Unis (11 aut.); University Hospital/Madrid/Espagne (12 aut.); Oslo City Department of Rheumatology, Diakonhjemmet Hospital/Norvège (13 aut.); Department of Rheumatology, University Hospital/Groningen/Pays-Bas (14 aut.); Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry/London/Royaume-Uni (15 aut.); Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover/Allemagne (16 aut.)</AF>
<DT>Publication en série; Compte-rendu; Niveau analytique</DT>
<SO>Rheumatology:(Oxford); ISSN 1462-0324; Royaume-Uni; Da. 1999; Vol. 38; No. 8; Pp. 779-788; Bibl. 93 ref.</SO>
<LA>Anglais</LA>
<EA>The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5-6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.</EA>
<CC>002B02L</CC>
<FD>Antiinflammatoire non stéroïde; Prostaglandin-endoperoxide synthase; Isozyme; Forme moléculaire; Pharmacologie; Mécanisme action; Spécificité; In vitro; In vivo; Homme; Traitement; Chimiothérapie</FD>
<FG>Oxidoreductases; Enzyme</FG>
<ED>Non steroidal antiinflammatory agent; Prostaglandin-endoperoxide synthase; Isozyme; Molecular form; Pharmacology; Mechanism of action; Specificity; In vitro; In vivo; Human; Treatment; Chemotherapy</ED>
<EG>Oxidoreductases; Enzyme</EG>
<SD>Antiinflamatorio no esteroide; Prostaglandin-endoperoxide synthase; Isozima; Forma molecular; Farmacología; Mecanismo acción; Especificidad; In vitro; In vivo; Hombre; Tratamiento; Quimioterapia</SD>
<LO>INIST-14528.354000089142290220</LO>
<ID>99-0464747</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006229 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 006229 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0464747
   |texte=   Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2

Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri